# EDGAR Filing Document

**Accession Number:** 0001782223
**File Stem:** 0001437749-25-037150
**Filing Date:** 2025-12
**Character Count:** 2255
**Document Hash:** 8b034125425189124dfd0b6f48eaa395
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-037150.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001437749-25-037150

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pyxis Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001782223
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831160910
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 321 HARRISON AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
- **BUSINESS PHONE:** (617) 221-9059

**MAIL ADDRESS:**
- **STREET 1:** 321 HARRISON AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118

December 8, 2025

<u>Via EDGAR</u>

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Lauren Hamill

Re: Acceleration Request for Pyxis Oncology, Inc.

<u>Registration Statement on Form</u><u> </u><u>S-3 (File No.</u><u> </u><u>333-291801)</u>

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pyxis Oncology, Inc. (the "**<u>Company</u>**"), hereby requests that the effective date of the Company's Registration Statement on Form S-3, Registration Number 333-291801 (the "**<u>Registration Statement</u>**") be accelerated so that the Company's Registration Statement will become effective at 5:00 P.M., Eastern Time or as soon thereafter as practicable, on December 9, 2025, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651.

*[Signature Page Immediately Follows]*

------

Very truly yours,<br>/s/ Jitendra Wadhane<br>Jitendra Wadhane<br> Principal Financial and Accounting Officer<br>

cc: Lara Sullivan, Pyxis Oncology, Inc. Asher Rubin, Sidley Austin LLP Istvan A. Hajdu, Sidley Austin LLP